ReWalk Robotics Ltd announces it has completed all internal design review processes to initiate clinical studies and production of Restore, a “soft suit” exoskeleton designed specifically for stroke patients.
Restore is specifically engineered to provide real-time adjustable walking assistance for stroke survivors who have mobility issues, via a compact, light, modular soft exosuit structure.
It is designed to transmit power to key joints of the legs with cable technologies, powered with software and mechanics that are similar to the technologies used in the ReWalk exoskeleton system for individuals with spinal cord injury. The cables are connected to fabric-based designs that attach to the legs and foot, thus lending the name “soft suit,” explains a media release from ReWalk Robotics, headquartered in Marlborough, Mass.
“Achieving successful laboratory testing and design review processes with the Restore system is a milestone that advances our efforts for commercialization,” says ReWalk CEO Larry Jasinski, in a media release. “The potential of these soft suit designs to expand the utilization of robotic technologies initially with stroke patients in rehab—and in the future for community use—is meaningful. Research into applications, such as multiple sclerosis and Parkinson’s Disease is the next horizon.”
The estimated target date for delivery of the Restore soft exoskeleton to the commercial market is sometime in 2018. Once clinical and laboratory testing of Restore is completed in the coming months, the company intends to apply for CE and FDA clearance. Commercialization will begin after clearance is granted, according to ReWalk Robotics.
[Source(s): ReWalk Robotics Ltd, PR Newswire]